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Abstract
A prospective laboratory-based multicenter study that collected all adult invasive pneumo-
coccal disease (IPD) episodes from 6 Spanish hospitals before (2008–2009) and after
(2012–2013). The 13-valent pneumococcal conjugate vaccine (PCV13) licensure was con-
ducted in order to analyze the impact of PCV13 introduction for children on adult IPD. A
total of 1558 IPD episodes were detected. The incidence of IPD decreased significantly in
the second period by -33.9% (95% CI, -40.3% to -26.8%). IPD due to PCV7 serotypes
(-52.7%; 95% CI, -64.2% to -37.5%) and to PCV13 additional serotypes (-55.0% 95% CI,
-62.0% to -46.7%) significantly decreased whereas IPD due to non-PCV13 serotypes
remained stable (1.0% 95% CI, -12.9% to 17.2%). IPD due to all PCV13 additional sero-
types significantly declined with the exception of serotype 3 (-11.3%; 95%CI -35.0% to
21.1%). IPD due to two non-PCV13 serotypes varied: serotype 6C that rose (301.6%; 95%
CI, 92.7% to 733.3%, p<0.001), related to the expansion of ST3866C, and serotype 8 that
decreased (-34.9%, 95%CI, -57.1 to -1.2, p = 0.049), related to a decline of the ST638. The
recombinant clone ST652111A (variant of ST1569V) increased in frequency. The decrease
of serotype 19A IPD was linked to a fall in those antibiotic susceptible clones. In the last
period, rates of penicillin- and cefotaxime-resistance remained under 10% and 4%, respec-
tively. Adult IPD decreased after the PCV13 introduction in Spain due to herd protection.
The spread of multidrug resistant clones (ST3866C, ST652111A) related to non-PCV13
serotypes needs further surveillance.
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Introduction
Streptococcus pneumoniae is a leading cause of severe disease worldwide, mainly affecting chil-
dren and the elderly populations. Pneumococcus infection can cause a broad spectrum of
invasive disease including bacteremic pneumonia, sepsis and meningitis. In 2015, it was esti-
mated that pneumoccal pneumonia was responsible for more than 1.5 million deaths world-
wide [1].
Based on the seven most frequent pediatric serotypes in the 1990’s (4, 6B, 9V, 14, 18C, 19F,
and 23F), the heptavalent conjugate vaccine (PCV7) was developed and introduced in 2000–
2001. Thereafter, the incidence of invasive pneumococcal disease (IPD) dramatically decreased
among children due to PCV7-serotypes, but also among adults due to herd protection [2,3].
This change was accompanied by a general decline in antibiotic resistance [3,4]. However, new
emerging serotypes were detected in the late PCV7 period [5–7] and the vaccine was improved
by including six additional serotypes (PCV13: 1, 3, 5, 6A, 7F, and 19A), whose frequency
increased after the PCV7 introduction. This PCV13 was licensed in Spain in 2010 for children
and in 2012 for adults. Children’s vaccination occurs mainly in the private market, with the
exception of the Autonomous Community of Madrid, which included universal PCV7 vacci-
nation for children in 2009 (3+1 schedule) that was replaced by PCV13 in June 2010 with a
coverage higher than 94% [8].
The purpose of our study was to evaluate the impact of the PCV13 introduction on the inci-
dence of adult IPD in Spain and its relationship with the dynamics of genotypes and serotypes.
To assess it, we designed a prospective multicenter study involving six Spanish teaching hospi-
tals from three Spanish regions that serve a population of approximately 4.000.000 adult inhab-
itants. The study was conducted throughout two periods: prePCV13 (2008–2009) and PCV13
(2012–2013).
Material and methods
A 4 year laboratory-based multicenter study involving 6 Spanish hospitals was conducted.
The included hospitals serve a global population of around 4.000.000 adult inhabitants from
three Spanish regions: Catalonia (Hospital Universitari de Bellvitge, Hospital Universitari
Vall d’Hebron, Hospital Universitari Germans Trias i Pujol and Corporació Sanitària Parc
Taulı́), Madrid (Hospital General Universitario Gregorio Marañón) and the Basque Country
(Hospital Universitario Donostia). An IPD episode was defined as the isolation of pneumo-
cocci from a normally sterile body site in a patient with clinical symptoms of infection
(http://wwwn.cdc.gov/nndss/conditions/invasive-pneumococcal-disease/case-definition/
2010/). All episodes of IPD among adults (18 years old) were prospectively collected. Only
one isolate per episode was included. Data collection included age, sex, source of isolate and
focus of infection. For comparison purposes, two periods were defined: pre-PCV13 (2008–
2009) and PCV13 (2012–2013). The PCV7 (targeting serotypes 4, 6B, 9V, 14, 18C, 19F and
23F) was licensed in 2001 and the PCV13 in 2010 (targeting PCV7 serotypes plus 1, 3, 5, 6A,
7F and 19A). The incidence of IPD was calculated using the total number of people as the
denominator which was obtained from data published by the regional governments (http://
www.madrid.org/iestadis/, http://www.idescat.cat/es/ and www.eustat.eus/). The distribution
of IPD episodes (using previous description) with missing serotype was assumed to be identi-
cal to those episodes with serotype information (45 episodes in the pre-PCV13 period and 10
in the PCV13 period).
This study was approved by the Clinical Research Ethics Committee of Hospital Universi-
tari de Bellvitge. Written informed consent was considered not necessary. Patients’ data were
anonymized for the purposes of this analysis.
Impact of PCV13 in adult IPD in Spain
PLOS ONE | https://doi.org/10.1371/journal.pone.0175224 April 6, 2017 2 / 13
Spain. Financial support was also provided by the
European Regional Development Fund (ERDF).
Competing interests: C.A., A.F. and J.L. have
received funding from Pfizer, unrelated to the
present study. All other authors declare no conflicts
of interest. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
Bacterial strains, serotyping and antimicrobial susceptibility
All available isolates [904 of 949 (95.3%) from the pre-PCV13 period and 599 of 609 (98.4%)
from the PCV13 period] were serotyped by Quellung reaction at the Spanish Reference Labo-
ratory. Susceptibility to 8 antimicrobials (penicillin, cefotaxime, erythromycin, clindamycin,
chloramphenicol, tetracycline, co-trimoxazole and levofloxacin) was tested by microdilution
method following The Clinical and Laboratory Standards Institute (CLSI) recommendations
and criteria [9]. For the epidemiological analysis of penicillin resistance, the oral therapy
breakpoints were applied. A multidrug resistant (MDR) isolate was defined as non-susceptible
to penicillin (MIC0.12) plus resistant to2 classes of non-βlactam antimicrobials [10].
Molecular typing
A selection of isolates was genotyped through PFGE and/or MLST. We analysed 378 isolates
obtained in the pre-PCV13 period (39.8%) including most penicillin- or macrolide- resistant
isolates (n = 162) and a selection of susceptible isolates (n = 206). We also analysed 474 isolates
collected in the PCV13 period (77.8%). The stains were selected according to major serotypes
and were representative of all the regions. All 852 isolates were typed by PFGE (SmaI). Band
patterns were visually compared following the criteria described by Tenover [11,12]. Major
PFGE patterns were described as those accounting for at least 5 isolates. In addition, 344 iso-
lates (22.1%) were typed using MLST (Multi Locus Sequence Type) [13] including at least one
representative isolate of each serotype-PFGE pattern combination.
Statistical analysis
Statistical analysis was performed using the SPSS software package (SPSS, version 14.0; SPSS,
Chicago, Illinois, USA). Statistical differences were assessed using the x2 or Fisher’s exact test
when appropriate. Statistical significance was established at α = 0.05. All reported p values are
two tailed. Incidence rates of IPD were defined as the number of episodes per 100.000 popula-
tion and 95% confidence intervals (CIs) were calculated.
Results
Study population
A total of 1558 IPD episodes were detected. Of these, 949 (60.9%) were collected in the pre-
PCV13 period and 609 (39.0%) in the PCV13 period. The overall mean age of patients was
61.6 years (range 18–107) and 925 (59.4%) episodes were detected in men. 839 episodes
(53.9%) occurred in young adults (18–64 years), of these 458 (54.6%) were aged below 50.
On the other hand, 719 episodes (46.1%) occurred in older adults (65 years), of these 434
(60.4%) were aged 75 or over. Demographic characteristics of the study population are shown
in Table 1. No differences were found between the two periods in male percentage or source of
isolates. The average age of the patients increased significantly during the study period (59.5 vs
64.7 years, p<0.001). The incidence of bacteremic pneumonia statistically decreased (9.03 vs
6.00 per 100 000 population, p<0.001) whereas the incidence of meningitis remained stable
(1.03 vs 0.87 per 100 000 population, p = 0.33).
Incidence of invasive pneumococcal disease (IPD)
The overall incidence of IPD decreased by -33.9% (95% CI, -40.3% to -26.8%) from 12.3 to 8.1
episodes per 100,000 population (Table 2). This decrease was statistically significant for all age
groups. IPD due to PCV7 serotypes decreased 2.0 to 1.0 episodes per 100,000 (-52.7%; 95% CI,
-64.2% to -37.5%) and IPD due to PCV13 additional serotypes declined from 5.7 to 2.6
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Table 1. Demographic characteristics, source of isolates and focus of infection of the study population.
pre-PCV13 (2008–2009) PCV13 (2012–2013) p*
Demographics Age mean (years) 59.5 64.7 <0.001
Male (%) 60.0 58.5 0.56
Source of isolates Episodes(n) % Episodes(n) %
Blood culture 822 86.6 520 85.4 0.43
Cerebrospinal fluid 47 5.0 41 6.7 0.14
Pleural fluid 54 5.7 28 4.6 0.35
Ascitic fluid 15 1.6 13 2.1 0.42
Other 11 1.2 7 1.1 0.99
Focus of infection Episodes(n) Incidence** Episodes(n) Incidence**
Pneumonia 700 9.03 451 6.00 <0.001
Meningitis 80 1.03 66 0.87 0.33
Peritonitis 33 0.43 23 0.31 0.22
Unknown focus 102 1.31 48 0.64 <0.001
Other 34 0.44 21 0.28 0.10
* p-value comparing pre-PCV13 and PCV13 periods
** Number of episodes per 100.000 population.
https://doi.org/10.1371/journal.pone.0175224.t001
Table 2. The incidence of IPD among adult patients before and after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in
Spain.
Age group (years) Serotypes Number of episodes Incidence* IPD change from pre-PCV13 to PCV13 (95% CI) P**
pre-PCV13 PCV13 pre-PCV13 PCV13
18–50 PCV7 52 19 1.1 0.4 -60.9 (-77.0 to -33.8) <0.001
Additional PCV13 155 39 3.3 0.9 -73.0 (-81.0 to -61.7) <0.001
non-PCV13 120 73 2.6 1.7 -34.8 (-51.3 to -12.8) 0.004
All 327 131 7.1 3.0 -57.1 (-65.0 to -47.4) <0.001
51–64 PCV7 38 19 2.5 1.2 -50.2 (-71.3 to -13.7) <0.001
Additional PCV13 109 56 7.2 3.6 -48.8 (-62.9 to -29.4) <0.001
non-PCV13 76 84 5.0 5.5 10.1 (-19.3 to 50.1) 0.58
All 223 158 14.7 10.3 -29.5 (-42.5 to -13.5) <0.001
65–74 PCV7 25 10 3.2 1.3 -60.6 (-81.1 to -17.9) <0.001
Additional PCV13 74 36 9.3 4.5 -52.0 (-67.8 to -28.6) <0.001
non-PCV13 61 79 7.7 9.8 27.7 (-8.6 to 78.4) 0.15
All 160 125 20.2 15.6 -23.0 (-39.0 to -2.6) 0.03
75 PCV7 42 24 5.2 2.8 -46.8 (-67.8 to -12.2) <0.001
Additional PCV13 102 61 12.6 7.0 -44.4 (-59.5 to -23.6) <0.001
non-PCV13 95 110 11.7 12.6 7.74 (-18.1 to 41.8) 0.63
All 239 195 29.5 22.4 -24.1 (-37.2 to -8.3) 0.005
All groups PCV7 157 72 2.0 1.0 -52.7 (-64.2 to -37.5) <0.001
Additional PCV13 440 192 5.7 2.6 -55.0 (-62.0 to -46.7) <0.001
non-PCV13 352 345 4.5 4.6 1.0 (-12.9 to 17.2) 0.91
All 949 609 12.3 8.1 -33.9 (-40.3 to -26.8) <0.001
*Estimated episodes per 100.000 population (95% CI)
** p-value comparing pre-PCV13 (2008–2009) and PCV13 (2012–2013) periods.
https://doi.org/10.1371/journal.pone.0175224.t002
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episodes per 100,000 (-55.0%; 95% CI, -46.7% to -62.0%). The incidence of IPD due to non-
PCV13 serotypes remained stable: 1.0% (95%CI, -12.9% to 17.2%), from 4.5 to 4.6 episodes per
100 000 population. Among patients aged 18–50 years, the incidence of IPD due to both
PCV13 and non-PCV13 serotypes showed a statistically significant decrease. In those groups
of patients aged>50 years, the IPD incidence due to PCV13 additional serotypes decreased
(p<0.001) whereas the IPD incidence due to non-PCV13 serotypes increased, although this
difference was not statistically significant. Since the hospitals are located in three different
Spanish regions, we also analyzed IPD changes by regions. The decrease of IPD due to PCV7
and PCV13 additional serotypes was more noticeable in Madrid than in the Basque Country
or Catalonia, although these differences were not statistically significant (Fig 1).
Serotypes
The overall IPD due to each of PCV13 additional serotypes (1, 3, 5, 6A, 7F and 19A) signifi-
cantly declined with the exception of IPD due to serotype 3 which remained stable (Fig 2 and
S1 Table). In addition, IPD due to serotypes 4, 14 and 23F, included in PCV7, also showed a
statistically significant decrease. No significant changes in the IPD due to non-PCV13 sero-
types was observed with the exception of IPD due to serotype 6C, which rose (301.6%; 95%CI,
92.7% to 733.3%), and IPD due to serotype 8, which decreased (-34.9%, 95%CI, -57.1% to
-1.2%). This decrease of serotype 8 was only linked to a reduction in the region of Madrid
Fig 1. Regional changes in IPD by serotype group. Dots expressed the percentage of change and lines the limits of 95% CI. The
decrease of IPD due to PCV7 and PCV13 additional serotypes was more noticeable in Madrid (the only region that included universal
children vaccination with PCV13) than in the Basque Country or Catalonia.
https://doi.org/10.1371/journal.pone.0175224.g001
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(-53.4%, 95% CI, -74.7% to -14.2%), remaining stable in the other regions (-9.8%, 95% CI,
-49.8% to 62.1%).
Antibiotic susceptibility
Table 3 shows the results of the antibiotic susceptibility to the 8 antimicrobials tested. Percent-
ages of non-susceptibility to penicillin (MIC0.12 mg/L, 22.7% vs 26.8%, p = 0.065), cefotax-
ime (MIC>0.5 mg/L, 10.1% vs 12.5%, p = 0.14), as well as the proportion of MDR isolates
(13.1% vs 16.2%, p = 0.08), showed a non-significant increase. Moreover, the proportion of
Fig 2. Incidence of invasive pneumococcal disease by serotype and by period. Asterisks indicate serotypes with statistically
significant changes (p0.05). All p values were 0.001 with the exception of serotypes 4 (0.012) and 8 (0.049).
https://doi.org/10.1371/journal.pone.0175224.g002
Table 3. Changes in antimicrobial susceptibility to eight antimicrobials before and after the PCV13 introduction.
Antimicrobial pre-PCV13 (2008–2009) PCV13 (2012–2013) p*
S# I R S I R
n (%) n (%) n (%) n (%) n (%) n (%)
Penicillin 734 (77.3) 155 (16.3) 61 (6.4) 446 (73.2) 107 (17.6) 56 (9.2) 0.043
Cefotaxime 852 (89.8) 83 (8.7) 14 (1.5) 533 (87.5) 54 (8.9) 22 (3.6) 0.006
Erythromycin 748 (78.8) 0 (0) 201 (21.2) 463 (76.1) 0 (0) 146 (23.9) 0.219
Clindamycin 770 (81.1) 0 (0) 179 (18.9) 483 (79.3) 0 (0) 126 (20.7) 0.399
Tetracycline 741 (78.1) 74 (7.8) 134 (14.1) 463 (76.1) 38 (6.2) 108 (17.7) 0.350
Chloramphenicol 880 (92.7) . . . 69 (7.3) 571 (93.7) . . . 38 (6.3) 0.415
Co-trimoxazole 675 (71.1) 54 (5.7) 220 (23.2) 441 (72.4) 21 (3.5) 147 (24.1) 0.607
Levofloxacin 926 (97.6) . . . 23 (2.4) 601 (98.7) . . . 8 (1.3) 0.147
* p-value comparing resistant isolates between periods. CLSI breakpoints were used.
# S: susceptible; I: intermediate; R: Resistant. Classical CLSI breakpoints for penicillin (oral: susceptible0.06mg/L; intermediate 0.12-1mg/L; and resistant
2mg/L) and cefotaxime (meningeal: susceptible0.5mg/L; intermediate 1mg/L; and resistant2mg/L) were used.
https://doi.org/10.1371/journal.pone.0175224.t003
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isolates fully resistant to penicillin or cefotaxime (MIC 2 mg/L) rose throughout the study
period (6.4% vs 9.2%, p = 0.043 and 1.5% vs 3.6%, p = 0.006, respectively). Nevertheless, the
incidence of IPD due to penicillin-resistant isolates was similar in both periods: 0.79 and 0.75
episodes per 100.000 population, respectively. Similarly, the incidence of IPD caused by those
cefotaxime-resistant isolates showed a non-significant increase (62.0%, 95% CI, -17.1% to
216.6%, p = 0.154) from 0.18 to 0.29 episodes per 100.000 population. IPD caused by MDR iso-
lates also remained stable: 1.60 and 1.31 episodes per 100.000 population, respectively (-17.7%,
95% CI, -36.8% to 7.1%, p = 0.14). There were no statistically significant differences for the
remaining antimicrobials.
Two PCV13 serotypes 19A (26.9% and 26.5%, respectively) and 14 (25.5% and 26.5%,
respectively) were the major serotypes associated with penicillin non-susceptibility in both
periods. Regarding erythromycin-resistance, a shift in the most frequent serotypes was found:
serotypes 8 (29.4%), 33F (12.9%), 19A and 23A (10.6% both) were the most frequent in the
first period and serotypes 6C (25.6%), 11A (16.3%) and 33F (11.6%) in the second period. In
this way, serotype 19A was the most frequent among dual-resistant strains (non-susceptibility
to penicillin and resistance to erythromycin) in both periods (36.1% vs 37.6%, respectively).
Two nonPCV-13 serotypes associated with dual resistance emerged in the second period: 24F
and 6C (15.8% both).
Molecular typing
After the analysis of 852 isolates by PFGE/MLST we were able to identify the major clones
related to specific serotypes previously described in Spain and other European countries [3,
14–17]. This analysis allowed us to classify genotypes according to their antimicrobial resis-
tance profile (See S2 Table). When comparing the two periods, major differences were found
in the genetic background of five serotypes (3, 6C, 9V, 11A and 19A). The increase in the IPD
caused by serotype 6C was related to an expansion of the clone ST3866C in all three regions,
which accounted for 14.3% (1 out of 7 studied) of the first period serotype 6C isolates and for
82.6% (19 out of 23 studied) of the second period isolates. For serotype 3, two major clones
were identified: ST180 and ST260. A shift in their proportions was observed, ST260 being pre-
dominant in the pre-PCV13 period (66.7%, 16 out of 24 studied), and ST180 in the PCV13
(61.4%, 35 out of 57 studied). In the second period, serotype 9V was only detected in Catalonia
and was associated with the emergence of a new penicillin-susceptible clone (ST2809V). This
clone accounted for 64.7% (11 out of 17 studied) of serotype 9V isolates of Catalonia, while in
the first period 42.1% of serotype 9V isolates (8 out 19 studied) belonged to the β-lactam-resis-
tant clone and were detected in all three regions. Among serotype 11A, we detected the emer-
gence of ST6521-MDR isolates (double locus variant of ST156) which accounted for 34.8%
(8 out of 23) of the studied strains, mainly in Madrid (5 episodes). Finally, among serotype
19A isolates, the major decline of its incidence was due a decrease of the penicillin- and macro-
lide-susceptible clones. In fact, we could identify an increase of isolates belonging to the MDR
ST320 clone (13.7%, 6 out of 44 and 57.1%, 24 out of 42 studied, respectively) in all three
regions.
Discussion
The present study demonstrated a herd protection of the adult population in Spain after the
PCV13 introduction for children, even when vaccination is mainly due under a private volun-
tary basis. Those results highlight the importance of the herd protection in the epidemiology
of the IPD when the target of vaccination is the pediatric population.
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In Spain, the estimated vaccine coverage for children remains around 60% for most regions,
with the exception of the Autonomous Community of Madrid where the vaccine is included
in the official vaccination schedule reaching a coverage above 95% [8, 18–19]. A recent pooled
analysis showed that the level of herd protection could be associated with the initial vaccine
coverage and the accumulated size of the vaccinated group [20]. In agreement with this, the
highest adult IPD decrease due to herd protection was observed in the Madrid region which
has the highest vaccine coverage. Although other factors could have influenced this higher
decrease in the Madrid region, we were not able to identify them.
Our results are similar to what was reported previously from other European countries,
from the US and from Israel [10, 21–25] and show a sharp decrease of the IPD only three years
after the PCV13 introduction. This IPD reduction was observed in all age groups and was
mainly linked to a reduction of the incidence of bacteremic pneumonia whereas the incidence
of meningitis remained stable [26]. However, it is remarkable that the mentioned studies
included pediatric populations with higher vaccine coverage than our study.
Overall, the incidence of non-PCV13 serotypes remained stable in the last period, with the
exception of a decrease in people aged<50 years. Although we have no explanation for this
decrease, it could be partially due to the existence of an outbreak of IPD due to Serotype
8-ST63 among young adults (mainly HIV-infected patients) in the region of Madrid over the
2004–2009 period (pre-PCV13); in fact among non-PCV13 serotypes, only serotype 8 IPD
decreased [27,28]. As expected, a reduction of incidence was observed for all PCV13 additional
serotypes (1, 3, 5, 6A, 7F and 19A) with the exception of serotype 3, which remained stable
(-11.3%, 95%CI -35.0% to 21.1%, p = 0.477). The impact of the PCV13 on the incidence of
serotype 3 is a controversial issue as there are different findings. For instance, a reduction of
IPD due to serotype 3 has been recently reported in England and Wales by Waight [25],
whereas no significant changes have been reported in the US and other European Countries
[10, 17, 22, 24]. This serotype is rarely found colonizing children [29,30] whereas it is one of
the first causes of IPD in adults as well as the fact that it is also associated with severe disease
and high mortality rates [31, 32]. In this way, we detected that serotype 3 was the leading cause
of IPD in the PCV13 period (12%) whilst it was only the fourth (9.1%) of the pre-PCV13
period (after serotypes 7F, 19A and 1). Probably, higher vaccine coverage and a longer vaccina-
tion period are needed to observe herd protection on the adult population [20]. However, the
expansion of the PCV13 vaccination to the adult population at risk could be more successful
to reduce the serotype 3 disease in adults. On the other hand, a change in their genetic back-
ground was observed when the local serotype 3 clone (ST260) has been partially replaced by
the widely disseminated serotype 3 clone (ST180). This shift could not be explained by antimi-
crobial pressure (both STs are fully antimicrobial susceptible) and probably reflects clonal fluc-
tuations of serotypes as previously described.
Regarding serotype 19A, despite the observed reduction of the IPD due to this serotype, the
number of isolates belonging to ST32019A increased over the study period, which is a matter of
concern since isolates of this clonal complex show a MDR pattern. These results are in agree-
ment with those published in the USA from the late PCV7 period and the early PCV13 [5,7,
33–35] but, as data of molecular epidemiology after PCV13 introduction in Europe is scarce,
we could not compare the occurrence of this phenomenon in other countries. Moreover, a
reduction of isolates belonging to ST32019A has also been detected in a pediatric population
from the USA [35] after the PCV13 introduction, even though this reduction was lower than
that observed for the susceptible clones. In fact, it seems that the persistence of the ST32019A
over the remaining 19A clones may be due to a combination of factors including an improved
colonizing ability [36], a change in their metabolic profile [37] and an enhanced resistance to
the antimicrobial stress due its MDR pattern.
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Regarding the non-vaccine serotypes, their incidence remained stable for most of them
with the exception of serotype 6C and the previously described serotype 8. In fact, serotype 6C
was the only non-vaccine serotype that significantly increased over the study period, related to
an expansion of the CC3866C. This multidrug resistant clone was identified as an emerging
lineage in Spain in 2009 [38] and a rise in its frequency has also been detected in the UK [39]
and France [16] after the PCV7 introduction and in the early PCV13 period. These data could
suggest a clonal replacement of those vaccine serotypes included in the serogroup 6 (6A and
6B). Nevertheless, it is remarkable that cross-reactivity between serotypes 6A and 6C has been
reported [40] and, therefore, the PCV13 introduction should theoretically protect against sero-
type 6C colonization and reduce their impact on the adult IPD, as observed by some authors
[10,41]. Our results could suggest a minor effect of the cross-reactivity between these serotypes
but also the need for a higher coverage to observe this impact. Moreover, several works that
were unable to detect a reduction of 6C isolates after the PCV13 introduction have been pub-
lished [24, 25, 42]. In any case, the expansion of this clone showing non-susceptibility to peni-
cillin, and macrolides and tetracycline resistance should be monitored.
Data regarding antimicrobial resistance after the PCV13 introduction is still scarce [10, 17,
23] but a decrease in the prevalence of penicillin- and cefotaxime-resistance has generally been
reported. In our study, although we have observed an increase in the proportion of non-sus-
ceptibility to penicillin, cefotaxime, and MDR isolates, the incidence of IPD due to these iso-
lates remained stable. These results were related to a drastic reduction of the IPD caused by
those prevalent susceptible clones (mainly ST3061, ST2895, ST39217F and ST120119A), to a sta-
bilization of the IPD caused by some multidrug resistant clones (ST23024F, ST32019A) and to
an emergence of new resistant clones (ST652111A and ST3866C). Of note, ST652111A is a
recombinant clone previously associated to serotypes 14 and 9V (included in the PCV13) and
it was mainly detected in Madrid, the region with higher coverage. This clone has been shown
to have the ability to evade the immune system [43]. On the other hand, the emergence of
ST3866C clone was detected in all three regions, even in Madrid. Then, probably, the cross-
reactivity of 6A with 6C needs a longer period as occurred for 6B and 6A [38].
The main strength of our study is the valuable information that it gives through a well char-
acterized population. Since the impact of the conjugate vaccines depends on, obviously, the
pre-existing proportion of serotypes of the target population, but also depends on the circulat-
ing clones, it is mandatory to study the pneumococcal population from a global perspective of
serotype-genotype. However, other factors could have contributed to the observed changes in
IPD such as variations in the overall population at risk of suffering IPD, which is the main lim-
itation of our study. In the same line, the selection of resistant isolates for molecular typing in
the pre-PCV13 period could have hidden the emergence or spread of antibiotic susceptible
clones. However, the clonal composition of Spanish invasive pneumococci in the prePCV13
period has been previously analyzed. Other limitations of this study are the lack of information
about the 23-valent pneumococcal polysaccharide vaccination (with coverage nearly 40% in
adults over 65), the immune status of the patients and the existence of comorbidities, whose
changes could have affected the incidence of IPD [44]. Finally, since up to 70% of the strains
were from Catalonia, this could be a bias of our study.
Conclusions
The decrease in the incidence of IPD observed in the period 2012–2013 was due to a decrease
in the incidence of PCV13 serotypes which demonstrates the importance of the herd immu-
nity. In spite of that, after the PCV13 introduction new clones have appeared (ST3866C,
ST652111A) and others have increased despite being clones related to serotypes included in the
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vaccine (ST1803 and ST32019A). In addition, in our geographical area, the rates of resistance to
penicillin and cefotaxime have increased in association to an expansion of MDR clones. On
account of all this, the surveillance of the pneumococcal invasive disease continues being nec-
essary as well as the development of broader conjugate vaccines.
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